medigraphic.com
Boletín Clínico de la Asociación Médica del Hospital Infantil del Estado de Sonora

2025, Number 2

<< Back Next >>

Bol Clin Hosp Infant Edo Son 2025; 42 (2)

Whooping cough, update

Guerrero BM, Reyes GU, Ayuzo VC, Gutiérrez CD, Reyes HKL, Quero HA, Virgen OC, Escobar CE, López CG, Vargas MME

Language: Spanish
References: 33
Page: 18-22
PDF size: 404.45 Kb.


ABSTRACT

Pertussis, caused by Bordetella pertussis, remains a highly contagious and vaccine-preventable disease. Despite global efforts, a post-pandemic resurgence has been observed, driven by factors such as decreased vaccination rates and the emergence of new strains. Comprehensive review of current literature was conducted, including epidemiological data from WHO, PAHO, and national reports from the Mexican Ministry of Health. Post-COVID-19 epidemiological changes and recent immunization strategies were analyzed. Global pertussis incidence increased by 800% compared to the previous year in Mexico. Major complications include pneumonia, pulmonary hypertension, and respiratory failure, particularly in infants under six months without complete vaccination. Acellular vaccines have shown limited long-term effectiveness. It is urgent to strengthen vaccination campaigns, especially for pregnant women and infants. Epidemiological surveillance and biological updates should be prioritized to control the resurgence of this disease.


REFERENCES

  1. Cherry JD. Pertussis: challenges today and for thefuture. PLoS Pathog. 2013; 9(7): e1003418.

  2. World Health Organization. Pertussis vaccines:WHO position paper. Wkly Epidemiol Rec. 2015;90(35): 433-60.

  3. Clark TA. Changing pertussis epidemiology:everything old is new again. J Infect Dis. 2014;209(Suppl 1): S10-S15.

  4. Heininger U, Cherry JD. The seroepidemiology ofBordetella pertussis infections. Pediatr Infect Dis J.2012; 31(1): 1-2.

  5. Warfel JM, Zimmerman LI, Merkel TJ. Acellular pertussisvaccines protect against disease but fail toprevent infection and transmission in a nonhumanprimate model. Proc Natl Acad Sci U S A. 2014;111(2): 787-92.

  6. Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B,Baxter R. Waning protection after fifth dose of acellularpertussis vaccine in children. N Engl J Med.2012; 367(11): 1012-9.

  7. World Health Organization. Immunization coverage.[Internet]. 2024. [Consultado el 10 de mayo de 2025].Disponible en: https://www.who.int/news-room/fact-sheets/detail/immunization-coverage

  8. Organización Panamericana de la Salud (OPS). LaPandemia de Covid-19 causa un importante retrocesoen la vacunación infantil, según se desprende delos nuevos datos publicados por la OMS y la UNICEF[Internet]. 2021. [Consultado el 10 de mayo de2025]. Disponible en: https://www.paho.org/es/noticias/15-7-2021-pandemia-covid-19-causa-importante-retroceso-vacunacion-infantil-segun-se

  9. Noticias ONU. La vacunación infantil en América Latina,De estar entre las más altas a estar entre lasmás bajas. [Internet]. United Nations; 2023. [Consultadoel 10 de mayo de 2025]. Disponible en: https://news.un.org/es/story/2023/04/1520292

  10. Cherry JD, Seaton BL. Patterns of Bordetella pertussisrespiratory illnesses: 1970–2010. Clin Infect Dis.2012; 54(4): 453-6.

  11. Clark TA, Messonnier NE, Hadler S. Pertussis control:time for something new? Trends in Microbiology.2012; 20(5): 211-3.

  12. Kline JM, Lewis T, Smith D. Global incidence of pertussisand impact of vaccination programs. Vaccine.2013; 31(5): 590-5.

  13. Secretaría de Salud de México. Boletín Epidemiológico:Semana 20, 2025. México: Secretaría de Salud;2025.

  14. Mooi FR, van Loo IH, King AJ. Adaptation of Bordetellapertussis to vaccination: a cause for its reemergence?Emerg Infect Dis. 2014; 10(11): 1894-901.

  15. Kilgore PE, Salim AM, Zervos MJ, Schmitt H-J. Pertussis:Microbiology, disease, treatment, and prevention.Clinical Microbiology Reviews. 2016 Jul; 29(3):449-86. DOI: 10.1128/cmr.00083-15

  16. 16. Centers for Disease Control and Prevention(CDC). Pertussis-United States, 1997–2000. MMWRMorb Mortal Wkly Rep. 2002; 51(4): 73-6.

  17. von König CHW, Halperin S, Riffelmann M, Guiso N.Pertussis of adults and infants. Lancet Infect Dis.2002; 2(12): 744-50.

  18. Centers for Disease Control and Prevention. Laboratorytesting for pertussis [Internet]. Centers for DiseaseControl and Prevention; 2024. [Consultado el10 de mayo de 2025]. Disponible en: https://www.cdc.gov/pertussis/php/laboratories/index.html

  19. Domenech de Cellès M, Magpantay FM, King AA,Rohani P. The impact of past vaccination coverageand immunity on pertussis resurgence. Sci TranslMed. 2018; 10(434): eaaj1748.

  20. Lee AD, Cassiday PK, Pawloski LC, et al. Clinicalevaluation and validation of Bordetella pertussisand Bordetella parapertussis real-time PCR assaysusing the FilmArray respiratory panel. J Clin Microbiol.2018; 56(9): e00303-18.

  21. Moreno-Pérez D, Baquero-Artigao F, Rodrigo C. TosFerina: Tratamiento y Prevención. Anales de PediatríaContinuada. 2008 Feb; 6(1): 45-9.

  22. Instituto Mexicano del Seguro Social. Vacunaciónen la embarazada. Guía de práctica clínica. 2010.

  23. Centers for Disease Control and Prevention. Recommendedantimicrobialagents for treatment and postexposureprophylaxis of pertussis: 2005 CDC guidelines.MMWR. 2005; 54(RR-14): 1-16.

  24. Forsyth KD, Wirsing von König CH, Tan T, Caro J, PlotkinS. Prevention of pertussis: recommendationsderived from the second Global Pertussis Initiativeroundtable meeting. Vaccine. 2007; 25(14): 2634-42.

  25. Meade BD, Plotkin SA, Locht C. Possible options fornew pertussis vaccines. J Infect Dis. 2014; 209(Suppl1): S24-S27.

  26. National Institute for Biological Standards and Control(NIBSC). Tosferina [Internet]. 2025 [Consultadoel 10 de mayo de 2025]. Disponible en: https://nibsc.org/science_and_research/bacteriology/pertussis.aspx

  27. Edwards KM, Berbers GA. Immune responses topertussis vaccines and disease. J Infect Dis. 2014;209(Suppl 1): S10-S15.

  28. Liu Y, Yu D, Wang K, Ye Q. Global resurgence of pertussis:A perspective from China. Journal of Infection.2024 Nov; 89(5).

  29. Nian X, Liu H, Cai M, Duan K, Yang X. Coping strategiesfor pertussis resurgence. Vaccines. 2023 Apr24; 11(5).

  30. Instituto Choiseul España. The Economic Impact ofVaccines. Spain: Instituto Choiseul España; 2017.

  31. Instituto Nacional de Salud. Protocolo de Vigilanciaen Salud Pública de Tos ferina. [Internet]. Colombia;2024. [Consultado el 10 de mayo de 2025]. Disponibleen: https://www.ins.gov.co/buscador-eventos/Lineamientos/Pro_Tos%20ferina%202024.pdf

  32. CONAVE. Aviso Epidemiológico. Aumento de casosde Tos ferina en México. [Internet]. 2025. [Consultadoel 10 de mayo de 2025]. Disponible en: https://www.gob.mx/salud/documentos/aviso-epidemiologico-por-aumento-de-casos-de-tos-ferina-en-mexico

  33. Kang HM, Lee T-J, Park SE, Choi S-H. Pertussis inthe post-covid-19 era: Resurgence, diagnosis, andmanagement. Infection & Chemotherapy. 2024 Nov20; 57(1). DOU: 10.3947/ic.2024.0117




2020     |     www.medigraphic.com